InMed Pharmaceuticals (INM)
NASDAQ:INM
Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $7.98
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$5.57M
Enterprise Value-$1.70M
Total Cash (Recent Filing)$5.20M
Total Debt (Recent Filing)$420.15K
Price to Earnings (P/E)―
Beta3.43
Next Earnings
Sep 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1142.54
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-0.30
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit-1.56
Enterprise Value/Ebitda0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA very low debt load reduces refinancing and interest-rate risk, giving management optionality to pursue drug development or M&A without immediate solvency pressure. That conservatively financed balance sheet supports multi-quarter R&D timelines while minimizing default risk.
Advancing Preclinical To IND PathwayConsistent cross-model preclinical efficacy and a documented regulatory timetable de-risks the program's technical pathway. A clear pre-IND/IND plan increases the probability of entering Phase 1 on schedule, preserving development value and enabling partner or syndicate interest over the next 6–18 months.
Strategic Capital And Pipeline Pivot Via Reverse MergerA reverse merger that brings substantial committed capital materially extends runway and shifts strategy toward a more funded migraine pipeline. The financing alleviates near-term funding risk and enables clinical execution and scale-up, improving chances to advance candidates and attract partners.
Bears Say
Severe Cash BurnPersistent, large negative operating and free cash flow indicates the company is consuming cash faster than it generates it, increasing reliance on external financing. Over several quarters this raises dilution and execution risk if promised financings or merger proceeds are delayed or reduced.
Low Gross Margins; Ongoing LossesDeclining gross margins and sustained operating losses suggest the current revenue mix and cost base do not support profitable scaling. Without margin recovery or higher-value collaborations, the business will struggle to convert revenue growth into self-sustaining cash flow over the mid term.
Significant Dilution And Control ShiftThe reverse merger and option repricings concentrate ownership and transfer control away from legacy investors, potentially subordinating legacy programs. Large dilution reduces incumbent shareholders' upside and raises execution uncertainty for legacy R&D assets and strategic priorities.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $7.98 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $5.57M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 18, 2026 which is in 111 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.733 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.733.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 3,314,063 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
35.81% Insiders
6.80% Other Institutional Investors
57.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---